13939-69-0

Basic information

• Product Name: 1-PIPERIDINECARBONYL CHLORIDE
• Synonyms: 1-PIPERIDINECARBONYL CHLORIDE;N-Piperidinecarbonyl chloride;1-Piperidinecarbonyl chloride (6CI,7CI,8CI,9CI);N-Chloroformylpiperidine;NSC 50227;piperidine-1-carbonyl chloride;1-Piperidinecarbonyl chloride 97%;1-(Chlorocarbonyl)piperidine
• CAS NO: 13939-69-0
• Molecular Formula: C₆H₁₀ClNO
• Molecular Weight: 147.6
• Product Categories: ACIDHALIDE;Building Blocks;Heterocyclic Building Blocks;Piperidines;Building Blocks;C5 to C7;Chemical Synthesis;Heterocyclic Building Blocks
• Mol File: 13939-69-0.mol
• Article Data: 29

Chemical Properties

• Boiling Point: 242 °C(lit.)
• Flash Point: 110 °C
• Appearance: /
• Density: 1.18 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.0421mmHg at 25°C
• Refractive Index: n20/D 1.459(lit.)
• PKA: -1.85±0.20(Predicted)
• CAS DataBase Reference: 1-PIPERIDINECARBONYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-PIPERIDINECARBONYL CHLORIDE(13939-69-0)
• EPA Substance Registry System: 1-PIPERIDINECARBONYL CHLORIDE(13939-69-0)

Safety Data

• Hazard Codes: C
• Statements: 34
• Safety Statements: 26-27-36/37/39-45
• RIDADR: UN 3265 8/PG 3
• WGK Germany: 3
• Hazardous Substances Data: 13939-69-0(Hazardous Substances Data)

Usage

Description

1-PIPERIDINECARBONYL CHLORIDE is an organic compound that serves as a versatile reagent in the synthesis of various pharmaceutical compounds. It is characterized by its ability to react with different types of molecules, making it a valuable asset in the development of new drugs and therapies.

Uses

1. Used in Pharmaceutical Industry:
1-PIPERIDINECARBONYL CHLORIDE is used as a reactant for the synthesis of various pharmaceutical compounds due to its reactivity and versatility in chemical reactions.
2. Used in HIV-1 Vpr Inhibitors:
1-PIPERIDINECARBONYL CHLORIDE is used as a reactant for the synthesis of coumarin-based HIV-1 Vpr inhibitors, which are designed to inhibit the replication of the virus and help in the treatment of HIV/AIDS.
3. Used in Antitumor Agents:
1-PIPERIDINECARBONYL CHLORIDE is used as a reactant for the synthesis of antitumor agents that act as potent chemosensitizers, enhancing the effectiveness of chemotherapy in cancer treatment.
4. Used in Enzyme Inhibition:
1-PIPERIDINECARBONYL CHLORIDE is used as a reactant for the synthesis of oxime carbamates, which are reversible inhibitors of fatty acid amide hydrolase, an enzyme involved in various physiological processes.
5. Used in Type 2 Diabetes Treatment:
1-PIPERIDINECARBONYL CHLORIDE is used as a reactant for the synthesis of dipeptidyl peptidase 4 (DPP-4) inhibitors, which are used in the treatment of type 2 diabetes by regulating blood sugar levels.
6. Used in Alzheimer's Disease Treatment:
1-PIPERIDINECARBONYL CHLORIDE is used as a reactant for the synthesis of bisarylmaleimide glycogen synthase kinase-3 (GSK-3) inhibitors, which have potential therapeutic applications in the treatment of Alzheimer's disease.
7. Used in Niemann-Pick Type C Disease Treatment:
1-PIPERIDINECARBONYL CHLORIDE is used as a reactant for the synthesis of lysosomal acid lipase inhibitors, which have potential therapeutic applications in the treatment of Niemann-Pick type C disease, a rare genetic disorder affecting lipid metabolism.

InChI:InChI=1/C6H10ClNO/c7-6(9)8-4-2-1-3-5-8/h1-5H2

Upstream product

• 110-89-4 piperidine 
• 75-44-5 phosgene 
• 4706-33-6 2-oxo-2-(piperidin-1-yl)acetic acid 
• 124-38-9 carbon dioxide 
• 5325-94-0 N-Ethoxycarbonylpiperidine 
• 3768-56-7 1-(trimethylsilyl)piperidine 
• 503-38-8 trichloromethyl chloroformate 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 2905-56-8 N-Benzylpiperidine 
• 301840-91-5 PdCl(CON(CH₂)5)(2,2'-dipyridine) 
• 7553-56-2 iodine 
• 301840-92-6 PdCl(CON(CH₂)5)(1,10-phenanthroline) 
• 128-09-6 N-chloro-succinimide 
• 7782-50-5 chlorine 

Downstream Products

• 98492-77-4 1-(aziridine-1-carbonyl)-piperidine 
• 1796-27-6 piperidine-1-carboxylic acid methyl ester 
• 5451-82-1 piperidine-1-carboxylic acid benzo[1,3]dioxol-5-yl ester 
• 6961-73-5 S-Ethyl-N,N-pentamethylen-thiocarbamat 
• 73790-59-7 Cyclopentylcarbamidsaeure-<2-diaethylamino-aethylester> 
• 5395-04-0 1,1'-carbonyldipiperidine 
• 119438-90-3 2-[tert-butoxycarbonyl-(piperidine-1-carbonylamino)-methyl]-5,5-dimethyl-thiazolidine-4-carboxylic acid benzyl ester 
• 104017-76-7 Piperidine-1-carboxylic acid N'-(3,5-bis-trifluoromethyl-phenyl)-hydrazide 
• 110175-07-0 (-)-3-<3-<(piperidylcarbonyl)oxy>phenyl>-N-propylpiperidine 
• 102423-80-3 2-hydroxy-2-phenyl-1-(piperidin-1-yl)ethan-1-one 
• 73280-62-3 Phenyl(piperidinocarbonyl)-thiocarbamidsaeure-O-methylester 
• 77452-91-6 Z-Piperidide of 2,3-diphenyl-1-aziridinecarboxylic acid 
• 20793-93-5 N(α)-benzyloxycarbonyl-N(τ)-piperidinocarbonyl-L-histidine methyl ester 

Relevant articles and documents

ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASES ASSOCIATED WITH P13K MODULATION

The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I), or a prodrug, solvate, enantiomer, st

Cannabidiol carbamate compound, pharmaceutical preparation, preparation method and application

The invention relates to a cannabidiol carbamate compound, a medicinal preparation, a preparation method and application, and belongs to the field of compounds for treating and preventing diseases related to aging, Alzheimer's disease and Parkinson's disease. The compound has a structure shown as a formula I or a pharmaceutically acceptable salt of the structure shown as the formula I. The compound has good butyrylcholine esterase resisting activity, shows good application prospect in treatment of Alzheimer's disease, and shows good application potential.

Novel cannabidiol?carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease

Cannabidiol (CBD) and rivastigmine have been launched as drugs for treating dementia and cholinesterases (ChEs) are ideal drug targets. This study focused on developing novel ChE inhibitors as drug leads against dementia through molecular modeling and fragment reassembly approaches. A potent carbamate fragment binding to active site gorge of BuChE was found via a docking-based structural splicing approach, thus, 17 novel compounds were designed by structural reassembly. Compound C16 was identified as a highly selective potent BuChE inhibitor (IC50 = 5.3 nM, SI > 4000), superior to CBD (IC50 = 0.67 μM). C16 possessed BBB penetrating ability, benign safety, neuroprotection, antioxidant and pseudo-irreversible BuChE inhibition (Kd = 13 nM, k2 = 0.26 min?1), showing good drug-like properties. In vivo studies confirmed that C16 significantly ameliorated the scopolamine-induced cognition impairment, almost entirely recovered the Aβ1?42 (icv)-impaired cognitive function to the normal level, showed better behavioral performance than donepezil and good anti-amyloidogenic effect. Hence, the potential BuChE inhibitor C16 can be developed as a promising disease-modifying treatment of AD.